Ann: Immutep reports supportive efficacy data from AIPAC study, page-13

IMO, this is a positive result and statistically significant.

The results are not groundbreaking and that was NOT expected by those who underestand the clinical aspect of the game, and for those who have some understanding of the the market, this is no disappointment (sorry if others who expected to be instant billionaires are disappointed - adds to their other concerns in this crisis).

We are on the right track and the track as hoped.

Those who ultimately decide on the value of this stock are the big guns, not a retail trader selling/buying a relatively small floating shares in retail hands.